Treating nasal polyps isn’t a one-and-done procedure. The complications from these growths, which develop in the lining of ...

The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...

SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections cut total nasal polyps score by ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal polyps to include adolescents as well, Regeneron Pharmaceuticals and Sanofi ...

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

Please provide your email address to receive an email when new articles are posted on . The need for systemic corticosteroids fell by 88%, and the need for surgery fell by 98%. Nasal polyp and ...

Tezepelumab-ekko is now approved for chronic rhinosinusitis with nasal polyps (CRSwNP), targeting thymic stromal lymphopoietin and marking its second indication after severe asthma. The phase 3 ...

Subjective — but not objective — olfactory improvements in patients who underwent endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps were maintained up to 6 months after surgery, ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab was the most used biologic. Allergists/immunologists prescribed the most biologics. Biologic ...